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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.04.032Objectives: Currently available therapies for acute and chronic lung diseases have
not been effective and have various problems associated with the technologies used.
We present a novel active mixing pump-lung with the goal of providing total respiratory
support to ambulatory patients.
Methods: The pump-lung is based on the concept of active mixing oxygenation
within a constrained vortex. The rotation of hollow-fiber membranes disrupts the
concentration boundary layer, increasing gas exchange efficiency, and simulta-
neously pumps the blood. Consequently, the amount of membranes required to
achieve gas transfer sufficient for total respiratory support is considerably small. A
series of studies, including computational design, experimental bench testing, and in
vivo animal experiments, have been performed to implement this concept into a
viable artificial pump-lung device.
Results: A series of pump-lung prototypes with a membrane surface area of 0.17 to
0.5 m2 were designed and characterized in vitro with bovine blood, demonstrating
extremely high gas exchange efficiency. The prototype with a gas exchange surface
area of 0.5 m2 was evaluated in calves. The device provided oxygen transfer of
approximately 115 mL/min for respiratory support of an animal for up to 5 days.
Conclusions: Progress to date suggests a high likelihood of success for an extra-
corporeal shorter-term lung that can be switched in and out like dialysis devices. Our
device is unique in that it incorporates an integrated pumping and active mixing
principle for excellent gas transfer and eliminates the need of the native right
ventricle’s ability to power blood through the artificial and natural lungs.
Our group has been interested in long-term cardiopulmonary support since1978, when we initiated our clinical program of extracorporeal membraneoxygenation (ECMO) for children and began a laboratory-based investiga-
tion of novel methods and devices for the task. With the gradual acceptance of lung
transplantation for end-stage pulmonary disease, we noted an unacceptable attrition
of patients waiting for scarce organs. We participated in advances made in mechan-
ical circulatory support for bridge to transplantation and destination therapy for
heart failure and hoped for a similar option for our patients with lung disease. Our
approach to the problem blended our knowledge of hollow-fiber membrane gas
transfer and of blood pumps.1,2 On the basis of our large experience with candidates
for lung transplantation, unlike other passively perfused devices,1,2 we reasoned that
in many patients right ventricular function would unreliably pump blood through
an oxygenator, and we virtually planned to fuse a blood pump on a large-fiber
oxygenator. We explored the possibility of combining active mixing and pumping
function in a compact unit. At present, there is an overall reduced cardiac surgical
market for perfusion and little corporate support for the development of an artificial
lung. We were fortunate to pursue our interest through the National Heart, Lung, and
Blood Institute (HL 065740). We set the following criteria as the drivers for the
design: (1) oxygen (O2) delivery rate of 250 mL/min and carbon dioxide (CO2)
elimination rate of 200 mL/min; (2) blood pumping of 5 L/min; (3) minimized
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priming volume (100 mL); (5) minimal blood cell injury
(hemolysis and platelet loss or activation); (6) anticoagula-
tion with warfarin; and (7) support for at least 21 days.
This report presents the results of the first 2 years of our
supported effort toward an ambulatory pump-lung and




The ambulatory pump-lung (APL) is based on the active convec-
tive mixing and pumping concept, which was achieved by rotating
a disk of microporous hollow-fiber membranes (Figure 1). A dual-
lumen shaft was used to supply gas through a spoke to the half of
the periphery of the disk and exit the waste gas from the other half
of the periphery. While the gas travels through the lumens of the
hollow fibers from one side of the disk to the other, gas exchange
occurs as the blood flows across the hollow-fiber membrane sur-
faces. The waste gas is collected on the opposite side of the disk,
where it then returns to the shaft for exhaust through another
spoke. The disk is housed in a specially designed housing with a
single axial inlet, primarily cylindrical volute, and single radial
outlet. When rotated in the housing, the centrifugal force caused by
the rotation of the disk draws the blood over the fibers and propels
it radially. The disk is rotated by using an electric DC motor
coupled to the disk shaft through a lip seal. The flow paths of the
supply gas and exhaust gas are also separated with lip seals. A
series of APL prototypes with 4-inch-diameter disks of gas ex-
change surface areas ranging from 0.17 to 0.5 m2 and with inlet
and outlet diameters of 0.5 inch were constructed with polypro-
pylene microporous hollow-fiber membranes. The priming volume
of the complete APL device is about 100 mL.
Fluid Dynamics Analysis
Our APL device required detailed understanding of the fluid reg-
imen to allow the geometric manipulations necessary to optimize
the relative velocity between fibers and blood. Computational fluid
dynamics (CFD) was leveraged to enhance understanding of these
key flow features. A general-purpose CFD code (CFX version 5.6;
Ansys Inc, Pittsburgh, Pa) was used to model the fluid flow within
Figure 1. Active mixing pump-lung (APL) device.the APL device.
974 The Journal of Thoracic and Cardiovascular Surgery ● OctoIn parallel, experimental flow visualization was also carried out
with laser-based fluorescent particle imaging.3 Neutrally buoyant
fluorescent microspheres 30 m in diameter (Duke Scientific, Palo
Alto, Calif) were seeded into a water-glycerin blood analog fluid as
markers of flow. The fluid had a viscosity of about 3.7 cP and a
density of 1.08 g/cm3 at room temperature (approximately 20°C)
to match the rheologic property of blood at high shear rates. The
flow fields at the region of interest were imaged with a high-
resolution digital CCD camera (Megplus 1.4; Eastman Kodak, San
Diego, Calif) with a digital frame grabber board (Oculus-F/64;
Coreco, Inc, St-Laurent, Quebec, Canada) hosted in a personal
computer under various operating conditions.
In Vitro Evaluation of APL
A closed circulatory loop with heparinized bovine blood (hemo-
globin, 12  1 g/dL) was used to evaluate the gas transfer
performance of the APL prototypes. The inlet blood was condi-
tioned with a Medtronic Maxima oxygenator to an oxygen satu-
ration of 65%  5%, a temperature of 37°C  2°C, a PCO2 of 45
 5 mm Hg, and a base excess of 0  5 mEq/L. The condition of
the inlet blood is consistent with the Association for the Advance-
ment of Medical Instrumentation standard for testing blood
oxygenators.4
Three samples of inlet and outlet blood were taken at each of
several device rotation rates and the gas flow/blood flow ratio was
set at 1:1. The partial pressures of O2 and CO2 were analyzed with
a blood gas analyzer (ABL5; Radiometer, Brønshøj, Denmark).
The concentration of hemoglobin and O2 saturation of the blood at
the inlet and outlet of the APL device were measured with a
co-oximeter (OSM3, Radiometer). The blood flow rate and pres-
sure head generated by the APL device were monitored by using
the transonic flow meter (T101; Transonic System Inc Ithaca, NY)
and physiologic pressure transducers (Model PX272; Edwards
Lifesciences, Irvine, Calif) with a patient monitor (Spacelabs,
Hillsboro, Ore). The oxygen gas flow rate was measured with a gas
flowmeter (822 Top-Trak; Sierra Instruments, Monterey, Calif).
CO2 concentration in the exhaust gas was determined by using a
CO2 analyzer (CO2-44B; Physio-Dyne, Quogue, NY). The oxygen
transfer rate was calculated by using the Fick principle with the
above measured quantities. The CO2 transfer was calculated on the
basis of the exit gas flow rate and the concentration of CO2.
A similar in vitro circulatory loop consisting of the APL device
and a temperature-controlled reservoir was constructed to evaluate
the hemolytic performance and biocompatibility. The heparinized
bovine blood was circulated for up to 6 hours. The pressures at the
inlet and outlet ports were measured by using the physiologic
pressure transducers with the patient monitor. The blood flow rate
was measured with the ultrasonic flowmeter. Interval blood sam-
ples during the experimental run were taken for complete blood
counts (platelets, white blood cells [WBCs], and hematocrit), as
well as plasma free hemoglobin (PFH). The complete blood count
of the blood samples was measured with a hematology analyzer
(Antech Diagnostics, Lake Success, NY). PFH was measured with
spectrophotometry.5
The pumping performance of the APL device was evaluated
over the full operating range of flow from shutoff to stall at 4
rotational speeds in the above circulatory flow loop. A series of
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the pumping capability of the APL device.
In Vivo Evaluation
The APL was surgically connected between the right atrium (RA)
and the right carotid artery of Jersey calves. During the course of
the study, all animals received humane care in accordance with the
“Guide for Care and Use of Laboratory Animals” (National Insti-
tutes of Health publication no. 86-23, revised 1996) and the
approved protocol by the Institutional Animal Care and Use Com-
mittee of the University of Pittsburgh.
A Thoratec ventricular assist device atrial cannula with a Te-
flon collar was placed in the RA via the right jugular vein and
secured with double purse-string sutures. A Thoratec ventricular
assist device 14-mm-diameter arterial cannula was anastomosed
end to side to the right carotid artery. Both cannulas were extended
to the upper right lateral chest wall using biocompatible tubing and
then connected to the APL mounted on the animal’s back. Anti-
coagulation was initiated with a loading dose of heparin to produce
activated clotting times of greater than 400 seconds (calf normal
value, approximately 150 seconds). After surgical intervention, a
slow infusion of heparin was begun, with the intention of main-
taining the activated clotting time at approximately 250 seconds.
Warfarin (10 mg) was started the evening after the operation and
periodically adjusted to maintain an international normalized ratio
of between 2.5 and 3.5. The heparin infusion was discontinued
thereafter.
Transonic flow probes were placed on the outlet cannulas.
Oxygen saturation was continuously monitored by using optical
oximetry probes attached to the inlet and outlet cannulas. Blood
pressure increase across the APL unit and animal arterial and
pulmonary artery (PA) pressures were continuously monitored
Figure 2. Pumping function of the active mixing pump-lung de-
vice as a blood pump.with the physiologic pressure transducers with the patient monitor.
The Journal of ThoraciThe blood compatibility of the APL was monitored in terms of
WBC and platelet counts, as well as PFH generation. Each animal
underwent a complete necropsy examination at the study termina-
tion. Special attention was paid to the device and the animal’s
lungs and pulmonary vasculature. Pulmonary vessels were
searched for the presence of emboli or abnormalities.
Results
In Vitro Pumping Function
As a blood pump, the ability of the APL device to pump
the blood is presented in Figure 2. This particular proto-
type had a membrane surface area of 0.17 m2. The
pumping function is expressed as the device-generated
pressure versus flow curves at a specific rotation speed.
The pressure versus flow curves exhibited a relatively flat
trend with increase of flow rate over a wide range at each
rotational speed. This feature indicates that the APL had
a wide operating range of flow rate against a large phys-
iologic pressure load.
Flow Characteristics
The APL device exhibited a unique flow characteristic. The
rotation of the hollow fibers generated a unique constrained
vortex in the space between the disk and APL upper housing
(Figure 3, A). This vortex encircled the axial inlet flow,
which entered the porous hollow fibers and was radially
spun out of the hollow-fiber bed to enter the above-
mentioned vortex. A similar vortex was also formed in
the space between the disk and APL lower housing, but
part of the fluid exited at the outflow tract. It was observed
that the portion of the constrained vortices recirculated back
to the hollow-fiber bed for further mixing. These unique
flow features specific to the rotating disk of fabric mem-
branes were observed under all operating conditions.
The CFD-predicted flow features with blood as the work-
ing fluid are consistent with the experimentally observed
Figure 3. A, Typical flow image of the active mixing pump-lung
device operated at 1000 rpm to generate a flow rate of 3 L/min
against 92 mm Hg. B, CFD-predicted flow velocity field within the
active mixing pump-lung device.flow patterns. Typical fluid velocity field at the APL mid-
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The CFD model of the APL was comprised of multiple
domains representing the porous rotor and the surrounding
fluid.
In Vitro Gas Transfer
Both the O2 and CO2 transfer rates of the APL prototypes
with a range of surface area are presented in Figure 4. With
a surface area of 0.5 m2, the APL device was capable of
delivering gas transfer rates of approximately 200 mL/min
for O2 and 200 mL/min for CO2 at a blood flow rate of 5
L/min. Although the normalized gas transfer rates decreased
with increase of the surface area from 0.17 to 0.5 m2, our
APL device with a surface area of 0.5 m2 still exhibited
extremely high gas transfer rates of 400 mL · min1 · m2
for O2 and 370 mL · min1 · m2 for CO2.
In Vitro Biocompatibility
The result of the hemolysis testing for a 0.17-m2 APL
device at a rated flow of 3.5 L/min is presented in Figure 5,
Figure 4. Gas exchange performance of the active mixing pump-
lung device versus surface area of membrane (Association for the
Advancement of Medical Instrumentation test conditions: 5 L/min;
normalized index of hemolysis, 0.068 g/100 L). VO2, Oxygen trans-
fer rate; VCO2, carbon dioxide transfer rate.A. The 6-hour hemolysis experiments indicated that the
976 The Journal of Thoracic and Cardiovascular Surgery ● OctoAPL device exhibited hemolytic characteristics on par with
those of a control system consisting of a roller pump and a
Medtronic Forte membrane oxygenator. The platelet and
WBC counts over 6 hours of in vitro testing are presented in
Figure 5, B. The platelet and WBC counts are within the
normal measurement error margins for both measurements.
It was also observed that no thrombus deposition was found
within the device during posttest examination. When the
surface areas were scaled up, the normalized index of he-
molysis from a 0.5-m2 APL prototype was 0.068 g/100 L,
which is in the range of the currently used blood pumps6
and commercial blood oxygenators.7
In Vivo Evaluation
In vivo animal experiments with the implantable APL de-
vice were conducted in 5 calves. The implantable APL
Figure 5. A, Results of the hemolysis testing over 6 hours on the
bench in accordance with the Association for the Advancement
of Medical Instrumentation standards at a rated flow of 3.5 L/min.
B, Platelet and white blood cell (WBC) counts decreased mod-
estly over the 6-hour testing of the active mixing pump-lung
device in vitro with bovine blood. MDT, Medtronic Forte oxygen-
ator/roller pump; PFH, plasma free hemoglobin; Hct, hematocrit.device used both uncoated and silicone-coated hollow-fiber
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flow rate was approximately 4 L/min. The sweep gas flow
rate was maintained at 1:1. All animals tolerated the surgical
implantation and recovered. During the 1-day in vivo bo-
vine experiments, the implanted APL device with uncoated
hollow-fiber membranes delivered a normalized oxygen
transfer rate of 350 mL · min1 · m2 (175 mL/min), which
was close to the in vitro result. One APL prototype with
silicone-coated fiber membranes was used for a 5-day in
vivo study. The oxygen gas transfer from the 5-day study is
shown in Figure 6. A temporary and unexplained decrease
in oxygen transfer occurred at 40 hours but was considered
most likely caused by change in animal position and kinking
of inlet cannulas. The mean oxygen transfer rate was ap-
proximately 110 mL/min. The silicone-coated hollow-fiber
membranes seemed to reduce the average gas transfer rate
modestly (175 mL/min to 110 mL/min) in this configuration.
PFH was increased from a preoperative level of 5 mg/dL to 28
mg/dL postoperatively and remained increased over the period
of 5 days. The platelet and WBC counts remained in the
normal physiologic ranges. Necropsy results exhibited that
there were no infarcts in the heart, lung, and kidney.
Discussion
Lung disease is America’s third largest cause of death.8 Adult
respiratory distress syndrome afflicts approximately 150,000
patients every year in the United States,9 and despite advances
in critical care, mortality remains between 30% and 70%.10
Currently available advanced therapies for patients with
chronic respiratory failure include mechanical ventilation
and ECMO. With mechanical ventilation, often the tidal
volume, airway pressure, and oxygen fraction necessary to
achieve sufficient gas exchange can further damage the
lungs,11 including barotrauma, volutrauma, and other iatro-
genic injuries. ECMO systems are associated with several
major problems: complexity of operation, bleeding caused
by the need for high levels of anticoagulation, and limited
mobility of the patient. Recent studies reported the novel
use of arteriovenous pumpless oxygenation that can benefit
some with acute lung failure, but this method has only been
used to date in the intensive care unit setting, and flow is
limited.12,13
Although lung transplantation has become an effective
treatment over the past 20 years, fewer than 1000 lung
transplantations are performed in the United States annually
because of the shortage of organ donors. Approximately
13% of patients listed for lung transplantation die while
waiting for scarce donor organs.14 Unlike heart and kidney
transplantation candidates, patients with irreversible acute
and chronic lung disease have no bridge option and must
live poor-quality lives, often terminally bound to a mechan-
ical ventilator and rarely receiving high-risk, last-option trans-
plantations. Implantable artificial lungs are always thought to
The Journal of Thoracibe a solution for these patients; however, these implantable
devices are still in the development stage.
The group at the University of Michigan has led the field
and favors a passive approach that includes the creation of
transverse mixing or cross-flow to arrange the hollow-fiber
membranes in a direction near perpendicular to the blood
flow.15,16 This group has stressed the development of a
low-resistance oxygenator that can be placed in a series with
the native lung (PA-PA connection) without exceeding the
ability of the right ventricle (RV) to manage flow through
both the artificial and natural lungs. Although the passive
designs improved gas transfer, this was only modest and
required the continued use of a large surface area and compli-
cated flow path and long exposure times that limited prospects
for biocompatibility.
To reduce the surface area, active mixing techniques
have been proposed to disrupt the formation of a boundary
layer, thus reducing the diffusion resistance to O2 and CO2
in the blood phase and increasing the gas exchange effi-
ciency. Active mixing techniques involve the introduction
of active secondary flows to disrupt the boundary layer
effect. Several active mixing designs have been proposed in
the past, including rotating disk, inner cylinder rotating
axial flow, and pulsed flow vortex shedding. Active mixing
techniques have been shown to cause as much as a 5-fold
increase in the rate of gas exchange.17-21 We based our
design on the concept of active convective mixing oxygen-
ation within a constrained vortex. Our APL exhibited gas
exchange performance far superior to that of commercially
available devices. The pressure-flow curves of our APL
Figure 6. Oxygen transfer performance of the active mixing
pump-lung device with a silicone-coated hollow-fiber membrane
during a 5-day in vivo bovine evaluation. VO2, Oxygen transfer
rate; APL, active mixing pump-lung.indicate that the APL device is an acceptable pump for
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range of pressures. Our device, however, as an extracorpo-
real lung, can be sealed to permit the advantage of active
mixing to translate into achievement of total body needs.
The evaluation of PFH generation and platelet and WBC
preservation is promising. Clearly this device operates with
a shear force, but transit time is very brief, which limits the
adverse effects. The hemolytic performance of our device is
comparable with that of acceptable blood pumps and com-
mercial membrane oxygenators. It was observed that no
thrombus deposition was found within the device during
posttest examination. Our initial in vivo experiment showed
that the APL device generated O2 transfer rates of approx-
imately 175 mL/min during 1-day acute studies and approx-
imately 110 mL/min during a 5-day study. Even the gas
transfer rate during the 5-day study has not reached the level
we like to have. However, the results with hemolysis and
biocompatibility are promising. We are pleased with the
initial performance and note that the functions of gas ex-
change and pumping are combined in the process. We have
met our initial goal of gas transfer and pumping at physio-
logic rates. This permits us to disregard the need for a
functional RV. For the APL to function for 21 days, it must
incorporate a hollow fiber that is plasma resistant and has a
minimal effect on the gas transfer performance, which is our
continued effort.
Conclusion
Presently, a long-term intracorporeal artificial lung is still a
dream. Progress to date by others and ourselves suggests a
high likelihood of success for extracorporeal shorter-term
lungs that can be switched in and out like dialysis devices.
Our device is unique in that it incorporates an integrated
pumping and active mixing principle for excellent gas trans-
fer. To us, the ability to eliminate concerns about the native
RV’s ability to power blood through the lung is a major
advantage. Certainly we acknowledge the risk of the com-
bined function should there be a loss of disk spin. On the
basis of our long experience with blood pumps, we believe
that the risk of failure is low and, importantly, that our
design does not result in hemolysis or loss of platelet and
WBC counts when the patient undergoes an operation at
physiologic rates of flow. We are encouraged by our pilot
work and continue to iterate the design with consideration
of function and biocompatibility.
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